LRRK2 inhibitors (CSIC/Harvard Medical School/CIBERNED)

N/A

Report date: 2025/01/26 18:24:59
NME

Base Information

Drug NameLRRK2 inhibitors (CSIC/Harvard Medical School/CIBERNED)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeucine-rich repeat serine/threonine-protein kinase 2 inhibitors
TargetsLeucine-rich repeat serine/threonine-protein kinase 2
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSpanish National Research Council
China Registration ClassN/A

Develop Information

Active CompaniesCentro De Investigacion Biomedica En Red De Enfermedades NeurodegenerativasSpanish National Research CouncilHarvard Medical School
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A